Transparency specifications in accordance with the FSA Code and AKG Directives (or guidelines)

According to the specifications of the FSA (Voluntary self-control for the Pharmaceutical Industry, registered association), the conditions and the scope of the support provided by member companies to the participants should be presented in a transparent manner for both the announcement as well as the execution of the Congress.

According to the directives (or guidelines) of the AKG (Pharmaceuticals and cooperation in health management, registered association) the member companies should work towards revealing their support for both the announcement and execution of the Congress by the host of the event. The publication of the type and scope of the overall support does not represent any obligation on the part of the AKG member companies and is provided voluntarily in this instance through a written agreement.

For the industry partners mentioned below we are informing regarding their overall support within the framework of the 58th ERA-EDTA Congress fully virtual according to their membership of the FSA or AKG:

ERA-EDTA 2021 Congress – fully virtual
Status: as per 31st May 2021
Astellas Pharma Ltd.62,450.00
AstraZeneca UK Limited172,450.00
B. Braun Avitum AG19,950.00
Bayer AG100,950.00
Boehringer Ingelheim GmbH & Co. KG19,950.00
Calliditas Therapeutics AB56,950.00
Chiesi Farmaceutici SPA85,450.00
Fluid-o-Tech s.r.l.6,950.00
Fresenius Kabi Deutschland GmbH55,450.00
Geistlich Pharma AG6,950.00
Hansa Biopharma AB68,708.50
Herco Wassertechnik GmbH5,950.00
Jafron Biomedical Co., Ltd.6,950.00
Joline GmbH & Co. KG2,950.00
NephroCan Inc.14,950.00
Novo Nordisk A/S83,500.00
Physidia SAS4,950.00
Sanofi Genzyme Corp.139,500.00
Vertex Pharmaceuticals Inc.52,450.00
Vifor Fresenius Medical Care Renal Pharma Ltd.270,247.40